An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids

Journal of Peptide Science

Volumn 5, Issue 3, 1999, Pages 141-153

  Stoev, S ^a   Cheng, L L ^a   Olma, A ^a,d   Klis, W A ^a   Manning, M ^a   Sawyer, W H ^b   Wo, N C ^c   Chan, W Y ^c  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Agonist; Aliphatic; Aromatic; Charged amino acids; Conformationally restricted; Polar

Indexed keywords

2 AMINOBUTYRIC ACID; ALANINE; ARGIPRESSIN DERIVATIVE; AROMATIC AMINO ACID; ASPARTIC ACID; GLYCINE; LEUCINE; NORLEUCINE; NORVALINE; OXYTOCIC AGENT; PHENYLALANINE; PROLINE; SERINE; THREONINE; TRYPTOPHAN; TYROSINE; VALINE; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

AMINO ACID SUBSTITUTION; ANTIDIURESIS; ARTICLE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALANINE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO ACIDS; ANIMALS; ARGININE VASOPRESSIN; DIURESIS; OXYTOCIN; PROTEIN CONFORMATION; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; VASOCONSTRICTOR AGENTS;

PUFFINUS AURICULARIS;

EID: 0032956960     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1387(199903)5:3<141::AID-PSC180>3.0.CO;2-6     Document Type: Article

References (63)

1. V. du Vigneaud, D.T. Gish and P.G. Katsoyannis (1954). A synthetic preparation possessing biological properties associated with arginine-vasopressin. J. Am. Chem. Soc. 76, 4751-5752.
2. V. du Vigneaud, M.F. Bartlett and A. Jöhl (1957). The synthesis of lysine-vasopressin. J. Am. Chem Soc. 79, 5572-5575.
3. B. Berde and R.A. Boissonnas. Basic pharmacological properties of synthetic analogues and homologues of the neurohypophysial hormones, in: Neurohypophysial Hormones and Similar Polypeptides. Handbook of Experimental Pharmacology, Vol. 23, B. Berde, Ed., p. 802-870, Springer Verlag, Berlin, 1968.
4. M. Lebl, K. Jost and F. Brtnik. Tables of analogs, in: Handbook of Neurohypophysial Hormone Analogs, Vol. 2, Part 2, K. Jost, M. Lebl and F. Brtnik, Eds, p. 127-267. CRC Press, Boca Raton, FL, 1987.
5. V. Hruby and C.W. Smith. Structure-activity relationships of neurohypophysial peptides, in: The Peptides, Vol. 8, S. Udenfriend and J. Meienhofer, Eds, p. 77-207. Academic Press, Orlando, FL, 1987.
6. M. Manning, L.L. Cheng, W.A. Klis, S. Stoev, J. Preybylski, K. Bankowski, W.H. Sawyer, C. Barberis and W.Y. Chan (1995). Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors, in: Oxytocin: Cellular and Molecular Approaches in Medicine and Research, R. Ivell and J. Russel, Eds, p. 559-583. Plenum Press. New York, 1995.
7. M. Manning, L.L. Cheng, S. Stoev, W.H. Sawyer, E. Tribollet, C. Barberis, N.C. Wo and W.Y. Chan. Novel potent and selective antagonists and radioiodinated ligands for oxytocin and vasopressin receptors, in: Neurohypophysts: Recent Progress of Vasopressin and Oxytocin Research, T. Salto, K. Kurokawa and S. Yoshido, Eds, p. 21-38, Elsevier, Amsterdam, 1995.
8. V. du Vigneaud, C. Ressler, J.M. Swan, C.W. Roberts, P.G. Katsoyannis and S. Gordon (1953). Synthesis of an octapeptide amide with the hormonal activity of oxytocin. J. Am. Chem. Soc. 75, 4879-4880.
9. R.H. Michell, C.J. Kirk and M.M. Billah (1979). Hormonal stimulation of phosphatidylinositol breakdown, with particular reference to the hepatic effects of vasopressin. Biochem. Soc. Trans. 7, 861-865.
10. S. Jard, C. Barberis, S. Audigier and E. Tribollet (1987). Neurohypophysial hormone receptor systems in brain and periphery. Prog. Brain Res. 72, 173-187.
11. C. Barberis and E. Tribollet (1996). Vasopressin and oxytocin receptors in the central nervous system. Crit. Rev. Neurobiol. 10, 119-154.
12. T. Kimura, O. Tanizawa, K. Mori, M.J. Brownstein and H. Okayama (1992). Structure and expression of a human oxytocin receptor. Nature 356, 526-529.
13. 1a vasopressin receptor. Nature 356, 523-526.
14. 1a vasopressin receptor. J. Biol. Chem. 269, 3304-3310.
15. 1b vasopressin receptor. J. Biol. Chem. 269, 27088-27092.
16. M. Birnbaumer, A. Seibold, S. Gilbert, M. Ishido, C. Barberis, A. Antaramian, P. Brabet and W. Rosenthal (1992). Molecular cloning of the receptor for human antidiuretic hormone. Nature 357, 333-335.
17. 2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357, 336-339.
18. 2[8-lysine] vasopressin and oxytocin receptors from a pig kidney cell line. Eur. J. Biochem. 215, 1-7.
19. P.G. Katsoyannis and V. du Vigneaud (1958). Arginine-vasotocin, a synthetic analogue of the posterior pituitary hormones containing the ring of oxytocin and the side chain of vasopressin. J. Biol. Chem. 233, 1352-1354.
20. M. Manning, E.J. Coy, W. H. Sawyer and M. Acosta (1973). Solid-phase synthesis and some pharmacological properties of 4-threonine analogs of vasopressins and vasotocin and of arginine-vasopressin and arginine-vasotocin. J. Med. Chem. 16, 463-466.
21. 8-oxytocine (lysine-vasotocine) et nouvelle synthèse de la lysine-vasopressine. Helv. Chim. Acta 43, 182-190.
22. R.D. Kimbrough, Jr. and V. du Vigneaud (1961). Lysine-vasotocin, a synthetic analog of the posterior pituitary hormones containing the ring of oxytocin and the side chain of lysine-vasopressin. J. Biol. Chem. 236, 778-780.
23. R.A. Boissonnas and S. Guttmann (1960). Synthèse d'analogues de l'oxytocine et de la lysine-vasopressine contenant de la phénylalanine ou de la tyrosine en position 2 et 3. Helv. Chim. Acta 43, 190-200.
24. S. Guttmann and R.A. Boissonnas (1960). Synthèse de dix analogues de l'oxytocine et de la lysine-vasopressine, contenant de la serine, de l'histidine ou du tryptophane en position 2 ou 3. Helv. Chim. Acta 43, 200-216.
25. C.W. Smith, F.M. Ferger and W.Y. Chan (1975). Synthesis and some pharmacological properties of [3-β-(2-thienyl)-L-alanine]-8-lysine-vasopressin. J. Med. Chem. 18, 822-825.
26. A. Buku, I.L. Schwartz, D. Gazis, C.L. Ma and P. Eggena (1985). Synthesis and biological activities of a fluorescent photoaffinity analog of vasopressin. Endocrinology 117, 196-200.
27. Z. Prochazka, J.E. Anacanas, J. Slaninova, A. Machova, T. Barth and M. Lebl (1990). Synthesis and biological properties of vasopressin analogues containing 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. Collect. Czech. Chem. Commun. 55, 1099-1105.
28. M. Manning, L.L. Cheng, S. Stoev, K. Bankowski, J. Przybylski. W.A. Klis, W.H. Sawyer, N.C. Wo and W.Y. Chan (1995). An exploration of the effects of L-and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin. J. Peptide Sci. 1, 66-79.
29. M. Manning, A. Olma, W.A. Klis, A. Kolodziejczyk, J. Seto and W.H. Sawyer (1982). Design of more potent antagonists of the antidiuretic response to arginine vasopressin. J. Med. Chem. 25, 45-50.
30. M. Manning, L.L. Cheng, S. Stoev, W.A. Klis, E. Nawrocka, A. Olma, W.H. Sawyer, N.C. Wo and W.Y. Chan (1997). Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists. J. Peptide Sci. 3, 31-46.
31. W.H. Sawyer, I. Deyrup-Olsen and A. W. Martin (1984). Immunological and biological characteristics of the vasotocin-llke activity in the head ganglia of gastropod molluscs. Gen. Comp. Endocrinol. 54, 97-108
32. B. Lammek, E. Konieczna, H.I. Trzeciak, A. Kozlowski, J. Szymkowiak, R. Stojko and G. Kupryszewski (1996). Surprising pharmacological activity of analogues designed by substitution of position 3 in arginine vasopressin (AVP) and 8-D-arginine vasopressin with L-2-naphthylalanine. J. Pharm. Pharmacol. 48, 316-319.
33. B. Lammek, M. Czaja, I. Derdowska, P. Rekowski, H.I. Trzeciak, P. Sikora, W. Szkrobka, R. Stojko and G. Kupryszewski (1997). Influence of L-naphthylalanine in position 3 of AVP and its analogues on their pharmacological properties. J. Peptide Res. 49, 261-268.
34. M. Manning, S. Stoev, L.L. Cheng, A. Olma, W.A. Klis, W.H. Sawyer, N.C. Wo and W.Y. Chan. An investigation of position three in arginine vasopressin (AVP), in: Peptides, J.P. Tam, Ed., Mayflower Scientific Ltd., England, 1998 (in press).
35. H. Rink (1987). Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methylester resin. Tetrahedron Lett. 28, 3787-3790.
36. E. Atherton and R.C. Sheppard. 'Reaction procedures and operating techniques' (Chapter 10) and 'Resin cleavage and purification' (Chapter 11), in: Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford, New York, Tokyo, p. 131-161, 1989.
37. G.B. Fields and R.L. Noble (1990). Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Peptide Protein Res. 35, 161-214.
38. R.B. Merrifield (1963). Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85, 2149-2154.
39. R.B. Merrifield (1986). Solid phase peptide synthesis. Science 232, 341-347.
40. J.M. Stewart and J.D. Young. Solid Phase Peptide Synthesis, Pierce Chemical Company, Rockford, IL, 1984.
41. M. Manning (1968). Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin. J. Am. Chem. Soc. 90, 1348-1349.
42. M. Manning, E. Coy and W.H. Sawyer (1970). Solid-phase synthesis of [4-threonine]oxytocin. A more potent and specific oxytocic agent than oxytocin. Biochemistry 9, 3925-3929.
43. 2 receptor antagonist design, in: Peptides 1996, R. Ramage and R. Epton, Eds. p. 819-820, 1998.
44. W. Koenig and R. Geiger (1970). New method for the synthesis of peptides: Activation of the carboxyl group with dicyclohexylcarbodiimide by using 1-hydroxy-benzotriazole as additive. Chem. Ber. 103, 788-798.
45. A. Bodanszky, M. Bodanszky, N. Chandramouli, J.Z. Kwei, J. Martinez and J.C. Tolle (1980). Active esters of 9-fluorenylmethyloxycarbonyl amino acids and their application in the stepwise lengthening of a pepide chain. J. Org. Chem. 45, 72-76.
46. M. Bodanszky and V. du Vigneaud (1959). A method of synthesis of long peptide chains using a synthesis of oxytocin as an example. J. Am. Chem. Soc. 81, 5688-5691.
47. M. Bodanszky and J.T. Sheehan (1964). Active esters and resins in peptide synthesis. Chem. Ind., 1423-1424.
48. V. du Vigneaud, C. Ressler, J.M. Swan, C.W. Roberts and P.G. Katsoyannis (1954). The synthesis of oxytocin. J. Am. Chem. Soc. 76, 3115-3121.
49. D.V. Hope, V.V.S. Murti and V. du Vigneaud (1962). A highly potent analogue of oxytocin, desamino-oxytocin. J. Biol. Chem. 237, 1563-1566.
50. J. Rivier, R. Kaiser and R. Galyean (1978). Solid phase synthesis of somatostatin and glucagon-selective analogs in gram quantities. Biopolymers 17, 1927-1938.
51. M. Manning, T.C. Wuu and J.W.M. Baxter (1968). The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15. J. Chromatogr. 38, 396-398.
52. P. Holton (1948). A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol. 3, 328-334.
53. W.H. Sawyer (1961). Biologic assays for oxytocin and vasopressin. Methods Med. Res. 9, 210-219.
54. J. Dekanski (1952). The quantitative assay of vasopressin. Br. J. Pharmacol. 7, 567-572.
55. R.A. Munsick (1960). Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology 66, 451-457.
56. M. Zaoral, J. Kolc and F. Šorm (1967). Synthesis of 1-deamino-8-D-γ-aminobutyrinevasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin. Collect. Czech. Chem. Commun. 32, 1250-1257.
57. M. Manning, L. Balaspiri, M. Acosta and W.H. Sawyer (1973). Solid phase synthesis of [1-deamino,4-valine]-8-D-arginine-vasopressin (dVDAVP), a highly potent and specific antidiuretic agent possessing protracted effects. J. Med. Chem. 16, 975-978.
58. M. Manning, S. Stoev, N.C. Wo and W.Y. Chan. Discovery of novel selective hypotensive analogues of a vasopressin antagonist, in: Peptides 1996, R. Ramage and R. Epton, Eds, p. 615-616, 1998.
59. W.Y. Chan, N.C. Wo, S. Stoev, L.L. Cheng and M. Manning. Discovery of novel selective hypotensive vasopressin peptides: A new vasodilating vasopressin receptor?, in: Vasopressin and Oxytocin: Synopsis of Recent Advances in Molecular, Cellular and Clinical Research, H.H. Zingg, D.C. Bichet and C. Bourque, Eds. Plenum Press, New York, 1998 (in press).
60. F. Gisin (1973). The preparation of Merrifield-resin through total esterification with cesium salts. Helv. Chim. Acta 56, 1476-1482.
61. 1)conotoxin GI analogs in the mouse diaphragm. Int. J. Peptide Protein Res. 34, 455-462.
62. α-Boc-glutamic acid. Int. J. Peptide Protein Res. 35, 215-218.
63. M. Felix, C.-T. Wang, E.P. Heimer and A. Fournier (1988). Application of BOP reagent in solid phase synthesis. II. Solid phase side-chain to side-chain cyclizations using BOP reagent. Int. J. Peptide Protein Res. 31, 231-238.